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Abstract Reverse cholesterol transport (RCT) describes the
process whereby cholesterol in peripheral tissues is trans-
ported to the liver where it is ultimately excreted in the form
of bile. Given the atherogenic role of cholesterol accumula-
tion within the vessel intima, removal of cholesterol through
RCT is considered an anti-atherogenic process. The major
constituents of RCT include cell membrane– bound lipid
transporters, plasma lipid acceptors, plasma proteins and
enzymes, and lipid receptors of liver cell membrane. One
major cholesterol acceptor in RCT is high-density lipopro-
tein (HDL). Both the characteristics and level of HDL are
critical determinants for RCT. It is known that phospholipid
transfer protein (PLTP) impacts both HDL cholesterol level
and biological quality of the HDL molecule. Recent data
suggest that PLTP has a site-specific variation in its function.
Moreover, the RCT pathway also has multiple steps both in
the peripheral tissues and circulation. Therefore, PLTP may
influence the RCT pathway at multiple levels. In this review,
we focus on the potential role of PLTP in RCT through its
impact on HDL homeostasis. The relationship between
PLTP and RCT is expected to be an important area in
finding novel therapies for atherosclerosis.
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Introduction
Atherogenesis is initiated by accumulation of cholesterol-
rich lipid strikes in the arterial wall [1]. Many processes have
been implicated in early atherogenesis, including lipoprotein
oxidation [2, 3], aggregation and retention [4–7], endothelial
alteration [1], monocyte recruitment, and foam cell forma-
tion [1]. Subsequent self-perpetuating chronic inflammatory
response leads to further immune reactions and lipid
deposition, which lead to atherosclerosis. One defense
mechanism for atherosclerosis is removal of cholesterol
from the vessel intima via reverse cholesterol transport
(RCT).
The general concept of RCT involves transport of
cholesterol from peripheral tissues and cells to the liver,
transforming it into bile acids, and finally eliminating it
from the body. RCT may prevent the formation and
development of atherosclerosis by decreasing cholesterol
levels in the plasma and in the wall of arteries. The RCT
pathway consists of multiple factors. First, there are lipid
transporters, which efflux cholesterol from peripheral
tissues [8–10]; second, there are lipid acceptors, such as
high-density lipoprotein (HDL) and its various subclasses
[8–11], which act as a mediator between peripheral tissues
and the liver; third, there are lipoprotein-associated proteins
and enzymes, such as lecithin: cholesterol acyltransferase
(LCAT) [12], cholesteryl ester transfer protein (CETP), and
phospholipid transfer protein (PLTP) [13], which are
involved in HDL remodeling and metabolism; and fourth,
there are liver receptors such as scavenger receptor class B
type I (SR-BI), which are important in removing cholesterol
from the circulation [14].
There is a growing body of evidence suggesting that
HDL mediates its atheroprotective effect through driving
cholesterol efflux from macrophage foam cells that reside
in vessel intima [11, 15, 16]. As a plasma cholesterol
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HDL particles are equally important to accomplish its
atheroprotective effect [8, 17, 18]. Therefore, several
cellular and plasma transfer proteins that are involved in
the process of the formation and remodeling of HDL play a
pivotal role in cholesterol efflux from macrophages.
Among the different transfer proteins that are active
either at cell membrane or in the circulation, PLTP and
CETP have long been studied for their remarkable role in
HDL metabolism. This review is mainly focused on the
latest data regarding the role of PLTP in HDL-mediated
RCT.
Reverse Cholesterol Transport
RCT is a potent defense mechanism against cholesterol
accumulation in peripheral tissues [19]. This process
involves the centripetal transport of excess cholesterol and
phospholipid from peripherally settled macrophages to the
liver for further metabolism and excretion through the bile-
fecal route [11, 16]. The first step of RCT is efflux of free
cholesterol from macrophages and other peripheral cells to
extracellular cholesterol acceptors [19, 20]. There are four
different pathways that work together to carry cholesterol
out of the macrophages to plasma acceptors. The major
route is through ATP-binding cassette (ABC) A1- and
ABCG1-mediated unidirectional active transport of free
cholesterol toward apolipoprotein A-I (apoA-I)–rich, lipid-
poor apolipoproteins (preβ-HDL) or HDL particles, respec-
tively [21, 22]. SR-BI and aqueous diffusion also promote
efflux of the excess cholesterol in a passive bi-directional
manner to mature HDL particles [23]. Macrophages and
foam cells have extensive contribution in pathogenesis of
the atherosclerotic lesions, and efflux of cholesterol from
these cells has been shown to have a significant role in
regression of an existing atheroma and reversing the process
of atherosclerosis [16]. In order to accomplish RCT, the
interaction between extracellular acceptors and cell sur-
face transporters is very critical [20]. During this step of
RCT, free cholesterol can be transferred to preβ-HDL, and
the HDL bound cholesterol is subsequently esterified by
LCAT. Accumulation of cholesteryl ester in preβ-HDL
converts it to the larger, spherical mature HDL particles
that are then taken up by the liver via the SR-BI [14, 24].
Alternatively, the cholesteryl ester can be transferred from
HDL to low-density lipoprotein (LDL), and the later can
be taken up by LDL receptors. The concentration and
composition of extracellular cholesterol acceptors are
determinants of the rate of cholesterol efflux. Furthermore,
plasma proteins such as PLTP, CETP, and lipases are
essentially involved in the process of HDL formation,
conversion, and remodeling. Therefore, these proteins
actively maintain the plasma level and biological properties
of HDL particles and potentially play an important role in
RCT.
High-Density Lipoprotein and Reverse Cholesterol
Transport
A high HDL cholesterol level has been mentioned as an
anti-atherogenic factor in progressive cohort studies and in
randomized clinical trials aimed at raising HDL levels.
Moreover, acute infusion of synthetic HDL or its principal
apolipoprotein, apoA-I, can induce the regression of
atheromatous plaque in humans. Indeed, there has been a
wealth of research demonstrating the beneficial processes in
which HDL participates. HDL plays a key role in RCT and,
importantly, facilitates the removal of cholesterol from
intra-lesion macrophages [25]. In addition, HDL has been
shown to protect against LDL-induced monocyte migration
into the sub-endothelial space in an endothelial cell/smooth
muscle cell co-culture system [26]. This is consistent with
the finding that HDL can blunt expression of endothelial
cell adhesion molecules [27]. HDL can protect against
oxidation of LDL or phospholipids [28]. Other aspects of
HDL function that are protective against atherosclerosis
include promoting endothelial function by stimulating nitric
oxide synthesis [29] and preventing platelet aggregation
and thrombin formation [30]. There are multiple aspects of
HDL function that are anti-atherogenic, and its role in RCT
is one of them. Different subclasses of HDL play major
roles as cholesterol acceptors in the extracellular region and
plasma [31]. Interestingly, a growing body of evidence has
shown that fruitful cholesterol efflux is dependent both on
high level of HDL cholesterol and on biological quality of
different HDL particles [17, 18]. The biological quality
refers to the size, shape, and composition of HDL
particles, which are notably various and dynamically
inter-convertible [32]. Evidently, each of the different
pathways of cholesterol efflux prefers a specific subclass
of the HDL particles as a cholesterol acceptor [32].
Therefore, the presence of different HDL subspecies and
dynamic conversion between these subspecies are deter-
minants for RCT. Human and mouse studies have pointed
out that preβ-HDL and mature HDL are the major
cholesterol acceptors in plasma [32]. Preβ-HDL is
produced by interaction, and subsequent lipidation, of
lipid-poor apoA-1 by ABCA1 or by HDL particle
remodeling in the circulation [19, 32]. One pathway for
HDL particle remodeling involves plasma PLTP. PLTP
fuses HDL particles generating larger HDL particles with
concomitant production of small preβ-HDL [33]. Given
its role in HDL metabolism, PLTP’sr o l ei nr e v e r s e
cholesterol transport deserves to be addressed.
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The relationship between PLTP structure and function is far
from resolved. However, some progress has been made.
PLTP belongs to a family of lipid transfer/lipopolysaccharide
binding proteins including lipopolysaccharide binding
protein (LBP), bactericidal/permeability increasing protein
(BPI), and CETP [34].
In terms of lipid transfer activity, PLTP has its own
characteristics. It has no neutral lipid transfer activity. PLTP
circulates bound to HDL and mediates the net transfer of
phospholipids betweenunilaminarvesiclesintoHDLandalso
the exchange of phospholipids between lipoproteins. The net
transfer of phospholipid into HDL results in the formation of
larger, less dense species. Plasma PLTP is also a nonspecific
lipidtransferprotein.SeveralstudieshaveindicatedthatPLTP
is capable of transferring all common phospholipids. Besides
phospholipids, diacylglycerol, α-tocopherol, cerebroside, and
lipopolysaccharides are likewise transferred efficiently [35].
Although CETP also can transfer phospholipids, there is no
redundancy in the functions of PLTP and CETP in the mouse
model [36].
The Effect of PLTP Overexpression on HDL Metabolism
Overexpression of PLTP in mice was achieved by adeno-
virus and adenovirus-associated virus (AAV)-mediated
infection. The former resulted in a 10- to 40-fold increase
in plasma PLTP activity [37, 38] .T h e s em i c ew e r e
characterized by increased preβ-HDL levels but decreased
α-HDL cholesterol levels. PLTP expression mediated by
AAV showed a prolonged pattern of overexpression that
resulted in a significant decrease of total cholesterol and
HDL cholesterol in C57BL/6 mice [38]. Transgenic mice
that overexpress human PLTP at high levels were also
generated. Compared with wild-type mice, they showed a
2.5- to 4.5-fold increase in PLTP activity in plasma. This
resulted in a 30% to 40% reduction of plasma HDL
cholesterol levels. Incubation of plasma from PLTP
transgenic animals at 37°C revealed a two- to threefold
increase in the formation of preβ-HDL compared with the
plasma from wild-type mice [39]. Overall, PLTP over-
expression causes a significant reduction of HDL levels in
the circulation.
The Effect of PLTP Deficiency on HDL Metabolism
So far, no PLTP deficiency has been found in humans. The
most useful information about PLTP deficiency was
obtained from PLTP gene knock out (KO) mice, which
demonstrated a complete loss of phosphatidylcholine (PC),
phosphatidylethanolamine (PE), phosphatidylinositol (PI),
sphingomyelin (SM), as well as a partial loss of free
cholesterol (FC) transfer activities [40]. Moreover, the in
vivo transfer of
3H phosphatidylcholine, either from very
low-density lipoprotein (VLDL) or HDL, was eliminated in
PLTP KO mice. On a chow diet, these mice showed a
marked decrease in HDL PL, FC, and apoA-I, demonstrat-
ing the important role of PLTP-mediated transfer of surface
components of triglyceride-rich lipoprotein in the mainte-
nance of HDL levels [40]. Additionally, the HDL of the
PLTP KO animals was enriched with protein and poor in
PC, and turnover studies showed a fourfold increase in the
catabolism of HDL protein and CE compared with wild-
type mice [41, 42]. Overall, PLTP deficiency also causes a
significant reduction of HDL cholesterol and phospholipid
levels in the circulation.
PLTP and Atherosclerosis
Both the physiologic function of PLTP in lipid homeostasis
and the pathologic role of PLTP in atherosclerosis devel-
opment are still being elucidated. PLTP expression is
increased in different pathologies associated with increasing
risk of coronary heart disease (CHD), such as obesity,
insulin resistance, and type I and type II diabetes [43]. In a
cross-sectional study, it was reported that serum PLTP
activity is increased in CHD patients [44]. Moreover, PLTP
activity is positively correlated with left ventricular systolic
dysfunction [45] and low HDL levels [46]. Contradictorily,
it also has been reported that lower PLTP activity without
significant change in total PLTP mass is a risk factor for
peripheral atherosclerosis [47]. Another study also has
shown that low PLTP is a risk factor for peripheral
atherosclerosis [48]. Importantly, a recent genome-wide
association (GWA) study has identified a single nucleotide
polymorphism (SNP) near the PLTP gene that is associated
with HDL and triglyceride (TG) levels. Interestingly, the
variant associated with higher HDL and lower TG also
correlated with higher PLTP transcript levels in the liver
[49]. This is the first evidence for a direct link between
PLTP and lipoprotein levels in humans. The effects on
HDL levels are consistent with the transgenic mouse
studies [40, 50], but the apparent lowering of triglyceride
levels in association with increased PLTP expression was
not predicted.
Valenta et al. [51] demonstrated that macrophage PLTP
alone has an atheroprotective effect in systemic PLTP-
deficient mice. This phenotype could be explained via
enhanced interaction of PLTP and ABCA1, which results in
stabilized HDL binding to ABCA1 and increased rate of
cholesterol and phospholipids efflux [52, 53]. Macrophage-
secreted PLTP also increases the concentration of pre-β
HDL within the arterial intima [54]. However, in a similar
setting, another study showed opposite results. In the study
of Vikstedt et al. [55], macrophage-secreted PLTP had an
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in this study was due to lack of PLTP activity in macro-
phages [55].
It has been reported that immunoreactive PLTP was
detected in histologic sections of human carotid artery [56,
57], where it is co-localized with CD-68–positive macro-
phages, suggesting in situ production. Synthesis of PLTP
was further demonstrated in cultured macrophages, and its
expression was upregulated by acetylated LDL treatment
[58, 59]. Moreover, in the atherosclerotic segments, PLTP
accumulated in extracellular matrixes, co-localizing with
apoA-I, apoE, and biglycan. These findings suggested that
PLTP might promote the binding of HDL to biglycan [57].
PLTP enhances cell-surface binding and remodeling of
HDL, improving its ability to promote cholesterol and
phospholipid efflux [53]. As underscored by recent bone
marrow transplantation studies, local PLTP expression in
macrophages could be protective as long as systemic PLTP
levels are not markedly elevated [51, 55, 60]. Therefore,
this set of data indicates that PLTP expressed by macro-
phages in the site of lesion may promote RCT, but the role
of systemic PLTP remains elusive.
Role of PLTP in Lipoprotein Oxidation
PLTP has vitamin E transfer activity that is important to
maintain vitamin E level in the tissues and in the
circulation. It is known that vitamin E-enriched LDL from
PLTP-deficient mice is resistant to oxidation and also is
much less likely to induce monocyte chemotactic activity
[42, 61]. Overexpression of PLTP decreases the vitamin E
content in LDL and increases its oxidation [38]. Accumu-
lating data showed that the function of PLTP in tissues is
different from its role in plasma. Studies on macrophage-
derived PLTP have demonstrated that PLTP deficient
macrophages have more basal cholesterol level and accu-
mulate more cholesterol in the presence of LDL [62].
Supplementary vitamin E in these animals normalizes the
phenotype [62]. Thus, PLTP can modulate cholesterol
deposition in macrophages through its role on oxidative
status inside the cells. We have shown that PLTP-deficient
hepatocytes secrete less apoB-containing lipoproteins and
that this is related to premature degradation caused by lack
of vitamin E and increased oxidation stress [63].
Role of PLTP in RCT
The role of PLTP in RCT (most of the studies were based on
mouse macrophage cholesterol efflux model) is controversial.
PLTP is highly expressed and regulated in macrophage cells,
and this suggests its potential involvement in lipid efflux.
Surprisingly, we found that the absence of PLTP does not
produce significant changes in macrophage cholesterol efflux
capacity [64], and this is also true for the macrophages that
overexpressed PLTP [65￿]. We also found that both PLTP-
deficient and PLTP-transgenic mouse plasma mediates less
macrophage cholesterol efflux, but after adjusting for differ-
ences in HDL cholesterol concentration (both PLTP-
transgenic and deficient mice have significantly lower HDL
cholesterol levels than wild-type mice) to the same levels as
wild-type mouse plasma, this difference was negated (Yeang
and Jiang, unpublished observation). Moreover, we found
that HDL from PLTP-deficient, PLTP-transgenic, and wild-
type mice has the same ability as a cholesterol acceptor
(Yeang and Jiang, unpublished observation). However, there
are many reports that indicate PLTP might promote or inhibit
cell cholesterol efflux.
Oram et al. [52] reported that exogenous PLTP can
mimic HDL apolipoprotein in removing cholesterol and
phospholipids from cells by the ABCA1 pathway. Unlike
apolipoproteins, however, PLTP requires the presence of
HDL acceptors for its optimum activity. PLTP, therefore,
a p p e a r st of u n c t i o na sa ni n t e r m e d i a r yi nt h et r a n s f e ro f
excess cellular lipids to lipoproteins through its interac-
tion with ABCA1 [52]. Oram et al. [66￿] also indicated
that an amphipathic helical region of the N-terminal
barrel of PLTP is critical for ABCA1-dependent choles-
terol efflux. Furthermore, Lee-Rueckert et al. [58]s t u d i e d
the ABCA1-dependent efflux of cholesterol from perito-
neal macrophages derived from PLTP-deficient mice and
Table 1 Role of PLTP in cholesterol efflux and reverse cholesterol transport
Negative role Positive role
PLTP transgenic and knock out mice do not show significant difference
in RCT [64, 65￿]
PLTP appears to be an intermediary factor in transfer of cholesterol
[52]
HDL from human PLTP/apoA-I double transgenic mice is less efficient in
RCT than apoA-I transgenic mice [70]
PLTP deficent macrophages are not able to efflux cholesterol [58]
High level of PLTP decreases the rate of macrophage RCT [71￿￿] Active PLTP increases HDL-mediated cholesterol efflux [69]
In hypertriglyceridemic diabetic patients, increased PLTP activity is
related to more cholesterol efflux [72]
apoA-I apolipoprotein A-I, HDL high-density lipoprotein, PLTP phospholipid transfer protein, RCT reverse cholesterol transport
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macrophages. They found that cholesterol efflux from
PLTP-deficient macrophage foam cells is defective and
that the defect can be corrected by robust stimulation of
the ABCA1-dependent pathway. These results support an
intracellular role for endogenous macrophage PLTP in
ABCA1-mediated cholesterol efflux from macrophage
foam cells [58]. Based on previous studies, PLTP is present
in plasma as two forms, a highly active (HA-PLTP) and a
lowly active (LA-PLTP) form [67, 68]. Vikstedt et al. [69]
reported that incubation of HDL in the presence of HA-PLTP
resulted in the formation of preβ-HDL and caused a 42%
increase in macrophage cholesterol efflux towards it,
whereas LA-PLTP neither formed preβ-HDL nor increased
cholesterol efflux. However, neither HA- nor LA-PLTP
enhanced cholesterol efflux to lipid-free apoA-I [69]. Based
on the above results, PLTP may promote macrophage
cholesterol efflux.
On the other hand, Moerland et al. [70] reported that in
cholesterol efflux studies from macrophages, HDL isolated
from human PLTP/human apoA-I double-transgenic mice
was less efficient than HDL isolated from human apoA-I
transgenic mice. Furthermore, it was found that the largest
subfraction of the HDL particles present in the double
transgenic mice was markedly inferior as a cholesterol
acceptor, as no labeled cholesterol was transferred to this
fraction. These data demonstrate that the action of human
PLTP in the presence of human apoA-I results in the
formation of a dysfunctional HDL subfraction, which is less
efficient in the uptake of cholesterol from cholesterol-laden
macrophages [70]. The same group of researchers investigated
the role of systemic and peripheral PLTP in macrophage
cholesterol efflux and RCT in vivo. They found that
macrophage cholesterol efflux and RCT to feces is impaired
in PLTP transgenic mice, and that elevation of macrophage
PLTP does not affect RCT, indicating that higher systemic
PLTP levels may promote atherosclerosis development by
decreasing the rate of macrophage RCT [71￿￿]. The same
experiment needs to be performed on PLTP-deficient mice.
Based on the above results, PLTP may inhibit macrophage
cholesterol efflux.
Contradictory results are also observed in human studies.
De Vries et al. [72] reported that cholesterol efflux from
fibroblasts to the HDL from normotriglyceridemic diabetic
plasma is unchanged, whereas efflux to HDL by the source
of hypertriglyceridemic diabetic plasma is enhanced, with
concomitant increased plasma PLTP activity. However,
Attia et al. [73] indicated that in diabetic patients with or
without CHD, PLTP activity was consistently increased
compared to the control group, whereas cellular cholesterol
efflux activity was significantly decreased. Table 1 summa-
rizes the reports related to the role of PLTP in cholesterol
efflux and RCT.
Conclusions
Does PLTP play an import role in RCT? The answer is still
not clear. PLTP clearly has a notable role in atherosclerosis
that may involve its impact on lipoprotein remodelling and
function. Based on published data together with our own
observations, PLTP may have some impact on RCT
(promoting or inhibiting), but the effect is marginal and
it is difficult to draw a clear-cut conclusion. Recent data
have shown that the properties of PLTP expressed locally
in macrophages and tissues may be different from its
function in circulation. It seems that PLTP has a pro-
atherogenic function in the circulation. However, our
knowledge about PLTP activity inside the cells is very
limited. To investigate the role of PLTP in atherogenicity,
other important aspects (other than RCT) need to be
explored, such as lipoprotein oxidation, inflammation,
apoB-containing particle assembly/secretion, intracellular
functions, and so on. Further, more epidemiologic studies
are needed to gain insights into the role of PLTP in
atherosclerosis. Lastly, discovery of humans with genetic
PLTP deficiency would be a major step toward the
elucidation of the role of this transfer protein in human
lipoprotein metabolism and atherosclerosis.
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